• About us

Onya Therapeutics is a biotech start-up focused on the development of products for wound management. We have a pipeline of products in late-stage preclinical and late-stage discovery.

As a spinout from Neem Biotech, based in Wales, UK, we have been able to leverage Neem’s chemistry and biology expertise in natural structures and their antimicrobial properties to build our pipeline of microbicidal drug candidates. This expertise has enabled us to advance novel wound treatments including the pre-phase II reformulation technology PP01/PP02 as well as novel quorum sensing and virulence factor inhibitors.

Our lead product, PP01, delivers an effective microbicide and astringent using a novel patch technology for the treatment of overly exuding wounds (40% of all chronic wounds). PP01 is initially being developed to treat diabetic foot ulcers.

PP02 is in late stage discovery and is being developed for prehospital emergency care by armed forces and first responders.


A world in which patients are able to embrace life again with confidence,  supported by advanced wound therapies. 

The team

Onya Therapeutics has brought together a team of expert scientists, clinicians, industry veterans and entrepreneurs on a mission to bring novel therapeutics to the challenges in wound care.

Thomas Hafner Founder & Chief Executive Officer
Dr Rachael McInnes Chief Scientific Officer
Steve Burt Financial Director
Thomas Hafner Chairman
Dr Bill Pigg Board Member
Professor Keith Harding Scientific Advisor
Carin Beumer Board Member
Partners & investors

We collaborate with strategic industry partners and investors, along with leading academic research institutions to support the development of our novel solutions in wound healing.

Please reach out if you’re interested in contributing clinical insights to our research or working with us to develop new products and technologies.